These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7716704)

  • 61. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
    Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
    Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [New pathogenic concept of lupus erythematosus disseminatus: clinical and therapeutic implications].
    Jacob L
    C R Seances Soc Biol Fil; 1987; 181(1):11-4. PubMed ID: 2954617
    [No Abstract]   [Full Text] [Related]  

  • 63. Autoantibodies against complement components in systemic lupus erythematosus - role in the pathogenesis and clinical manifestations.
    Hristova MH; Stoyanova VS
    Lupus; 2017 Dec; 26(14):1550-1555. PubMed ID: 29092674
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?
    Binard A; Le Pottier L; Saraux A; Devauchelle-Pensec V; Pers JO; Youinou P
    J Autoimmun; 2008; 30(1-2):63-7. PubMed ID: 18155417
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pathways leading to an immunological disease: systemic lupus erythematosus.
    Zharkova O; Celhar T; Cravens PD; Satterthwaite AB; Fairhurst AM; Davis LS
    Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i55-i66. PubMed ID: 28375453
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The epigenetic face of systemic lupus erythematosus.
    Ballestar E; Esteller M; Richardson BC
    J Immunol; 2006 Jun; 176(12):7143-7. PubMed ID: 16751355
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Tumour necrosis factor and other cytokines in murine lupus.
    Theofilopoulos AN; Lawson BR
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I49-55. PubMed ID: 10577973
    [No Abstract]   [Full Text] [Related]  

  • 68. Systemic lupus erythematosus and atherosclerosis: Review of the literature.
    Frieri M; Stampfl H
    Autoimmun Rev; 2016 Jan; 15(1):16-21. PubMed ID: 26299985
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The beneficial effects of treatment with tamoxifen and anti-oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulations.
    Dayan M; Zinger H; Kalush F; Mor G; Amir-Zaltzman Y; Kohen F; Sthoeger Z; Mozes E
    Immunology; 1997 Jan; 90(1):101-8. PubMed ID: 9038719
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cytokines and systemic lupus erythematosus.
    Dean GS; Tyrrell-Price J; Crawley E; Isenberg DA
    Ann Rheum Dis; 2000 Apr; 59(4):243-51. PubMed ID: 10733469
    [No Abstract]   [Full Text] [Related]  

  • 71. Regulatory T cells in systemic lupus erythematosus.
    Ohl K; Tenbrock K
    Eur J Immunol; 2015 Feb; 45(2):344-55. PubMed ID: 25378177
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
    Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
    Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Systemic lupus erythematosus.
    Pisetsky DS
    Curr Opin Immunol; 1991 Dec; 3(6):917-23. PubMed ID: 1793536
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Diagnostic, prognostic and therapeutic aspects of systemic lupus erythematosus and rheumatoid arthritis.
    Weyand C
    Klin Wochenschr; 1990; 68 Suppl 21():55-63. PubMed ID: 2198390
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Systemic lupus erythematosus--disease management.
    Gourley MF
    Springer Semin Immunopathol; 1994; 16(2-3):281-94. PubMed ID: 7716709
    [No Abstract]   [Full Text] [Related]  

  • 76. Urinary biomarkers in lupus nephritis.
    Aragón CC; Tafúr RA; Suárez-Avellaneda A; Martínez MT; Salas AL; Tobón GJ
    J Transl Autoimmun; 2020; 3():100042. PubMed ID: 32743523
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.
    Urowitz MB; Isenberg DA; Wallace DJ
    Lupus Sci Med; 2015; 2(1):e000104. PubMed ID: 26301100
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
    Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
    PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.
    López-Pedrera C; Aguirre MÁ; Barbarroja N; Cuadrado MJ
    J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20936125
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
    Sharabi A; Dayan M; Zinger H; Mozes E
    J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.